Blog
RSS FeedPosted by Michael Wonder on 07 Nov 2023
Germany, Belgium and France among those hit hardest as Commission’s Pharma-legislation proposals risk Europe losing a third of its share of global R&D by 2040
6 November 2023 - The European Federation of Pharmaceutical Industries and Associations (EFPIA) is publishing new research which assesses the ...
Posted by Michael Wonder on 25 Jul 2023
Peter Mac increases manufacturing centre for gene therapy bringing new hope to cancer patients
25 July 2023 - Australia’s first biomedical manufacturing facility has opened in Melbourne and will boost lifesaving therapy for cancer patients ...
Posted by Michael Wonder on 13 Apr 2023
Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say
13 April 2023 - If courts affirm US District Judge Matthew Kacsmaryk’s decision to suspend the FDA’s approval, it could make ...
Posted by Michael Wonder on 03 Mar 2023
Bipartisan senators introduce bill to close pharma competition loophole
1 March 2023 - Senators Maggie Hassan and Mike Braun on Wednesday reintroduced legislation intended to close a loophole that ...
Posted by Michael Wonder on 19 Jan 2023
The battle over European drug pricing
19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...
Posted by Michael Wonder on 21 Nov 2022
Big pharma may have to reveal government deals in WHO's draft pandemic rules
17 November 2022 - Pharmaceutical companies could be made to disclose prices and deals agreed for any products they make ...
Posted by Michael Wonder on 29 Sep 2022
Europe's generic drugmakers say they may cut output due to energy bills
28 September 2022 - Europe's drugmakers have warned they may stop making some cheap generic medicines because of surging electricity ...
Posted by Michael Wonder on 15 Sep 2022
FDA’s drug industry fees fuel concerns over influence
15 September 2022 - The pharmaceutical industry finances about 75% of the agency’s drug division, through a controversial program that ...
Posted by Michael Wonder on 29 Aug 2022
FDA boldly bows to big pharma at Americans’ expense
29 August 2022 - A Wall Street Journal headline went this way: “Latest Covid Boosters Are Set to Roll Out ...
Posted by Michael Wonder on 02 Aug 2022
FDA official: patients play an increasing role in rare disease drug development
1 August 2022 - Patients have a critical role in drug development, from identifying unmet medical needs to assessing meaningful ...
Posted by Michael Wonder on 26 Jul 2022
Despite their anger over high drug prices, Americans are giving pharma credit for helping contain COVID-19
26 July 2022 - Nearly three quarters of Americans give the pharmaceutical industry credit for helping contain COVID-19 — and for ...
Posted by Michael Wonder on 19 Jun 2022
IP waiver for COVID vaccines is a threat to future innovation
20 June 2022 - The decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have ...
Posted by Michael Wonder on 13 Jun 2022
IP waiver for COVID vaccines misses the mark in vaccinating the world
14 June 2022 - Vaccinating the world remains a priority and proposals to weaken the intellectual property for COVID-19 vaccines ...
Posted by Michael Wonder on 15 Mar 2022
Drug industry says EMA’s PRIME scheme useful but could be improved
14 March 2022 - Eligibility criteria for admission to the EMA's priority medicines (PRIME) scheme are too strict to facilitate ...
Posted by Michael Wonder on 30 Jan 2022
Medicines regulator pilot probes pharma delays in market launches
25 January 2022 - The European Medicines Agency wants to get a better understanding of drug companies’ commercial intentions and why. ...